Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Infinity Pharmaceuticals, Inc. (INFIQ) had Consolidated Net Income/Loss of $-44.37M for the most recently reported fiscal year, ending 2022-12-31.
| Income Statement Financials | |
$2.59M |
|
$-44.37M |
|
-- |
|
$2.59M |
|
$47.44M |
|
$-44.84M |
|
$0.47M |
|
$-44.37M |
|
$-44.37M |
|
$-44.37M |
|
$-44.37M |
|
|
Consolidated Net Income/Loss |
$-44.37M |
$-44.37M |
|
$-44.84M |
|
$-44.39M |
|
89.25M |
|
89.25M |
|
$-0.50 |
|
$-0.50 |
|
| Balance Sheet Financials | |
$40.30M |
|
$0.80M |
|
$1.85M |
|
$42.15M |
|
$13.63M |
|
-- |
|
$47.57M |
|
$61.20M |
|
$-19.05M |
|
$-19.05M |
|
$-19.05M |
|
89.41M |
|
| Cash Flow Statement Financials | |
$-42.43M |
|
$-0.06M |
|
$0.07M |
|
$80.88M |
|
$38.47M |
|
$-42.41M |
|
$3.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1729.42% |
|
-1729.42% |
|
-1711.76% |
|
-1711.11% |
|
-1711.11% |
|
$-42.45M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
-- |
|
-- |
|
232.90% |
|
232.90% |
|
-105.26% |
|
232.90% |
|
$-0.21 |
|
$-0.48 |
|
$-0.48 |
|